Efficacy of Novel Multimodality Pigment-Correcting Serum for Moderate to Severe Facial Hyperpigmentation, Including Melasma, in a 12-Week, Split-Face, Double-blind, Randomized Controlled Trial

Main Article Content

Elizabeth T. Makino, BS, CCRA, MBA
Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA

Priscilla Huang, BA
Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA

Summer F. Acevedo, PhD
SGS Inc., Richardson, TX, USA

Cheryl Vaughan, PhD
SGS Inc., Richardson, TX, USA

Rahul C. Mehta, PhD
Allergan Aesthetics, an AbbVie Company, Irvine, CA, USA

Keywords

pigmentation disorders, melanosis, brightening, skincare, lotus sprout extract, even and correct advanced brightening treatment

References

1. Rittie L, Fisher GJ. Cold Spring Harb Perspect Med. 2015;5:a015370.

2. Plensdorf S, et al. Am Fam Physician. 2017;96:797-804.

3. Grimes PE, et al. Int J Womens Dermatol. 2019;5:30-6.

4. Shokeen D. Cutis. 2016;97:E9-E11.

5. Cestari TF, et al. An Bras Dermatol. 2014;89:11-25.

6. Alexis AF, et al. J Drugs Dermatol. 2019;18:616-22.

Article Sidebar

Poster PDF
Published
Mar 13, 2023
DOI https://doi.org/10.25251/skin.7.supp.190

Article Details

How to Cite
Makino, E., Huang, P., Acevedo, S., Vaughan, C., & Mehta, R. (2023). Efficacy of Novel Multimodality Pigment-Correcting Serum for Moderate to Severe Facial Hyperpigmentation, Including Melasma, in a 12-Week, Split-Face, Double-blind, Randomized Controlled Trial. SKIN The Journal of Cutaneous Medicine, 7(2), s190. https://doi.org/10.25251/skin.7.supp.190
Issue
Vol. 7 No. 2 (2023): March Issue & Poster Presentations from WCH23 Dermatology Conference®
Section
Disorders of Pigmentation
Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All authors retain copyright in their articles. All articles published open access allowing for immediate free access to the work and permitting any user to read, download, copy, distribute, print, search, or link to the full texts of articles, crawl them for indexing, pass them as data to software or use them for any other lawful purpose. Permitted reuse is defined by  the following user license:
 

Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation. 

Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.ca/ojs/.

Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.

Most read articles by the same author(s)